News Swiss biotech Noema raises $112m for Roche castoffs Cash will fund mid-stage trials in epilepsy, trigeminal neuralgia, and other CNS conditions.
News NICE recommends cannabinoid med for severe epilepsy Global biopharma Jazz Pharmaceuticals’ Epidyolex/Epidiolex (cannabidiol), developed by GW Pharmaceuticals and now part of Jazz, has received
News Wales is first UK country to fund GW's Epidyolex for tuberou... Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by
News Swiss start-up Noema raises $59m to develop neurology drugs ... Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche.
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.